We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Could Help Identify Early Skin Cancer

By LabMedica International staff writers
Posted on 05 Sep 2017
Newly developed technology uses artificial intelligence (AI) to help detect melanoma skin cancer earlier than current methods and to help reduce the number of unnecessary biopsies. More...
The AI-based method employs machine-learning software to analyze images of skin lesions and to provide doctors with objective data on telltale biomarkers of melanoma.

"This could be a very powerful tool for skin cancer clinical decision support," said Alexander Wong, professor at University of Waterloo (Waterloo, ON, Canada), "The more interpretable information there is, the better the decisions are." Prof. Wong developed the technology in collaboration with Daniel Cho, former PhD student at Waterloo, David Clausi, professor at Waterloo, and Farzad Khalvati, adjunct professor at Waterloo and scientist at Sunnybrook.

Currently, dermatologists largely rely on subjective visual examinations of skin lesions (e.g. moles) to decide if patients should undergo biopsies to diagnose the disease. The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on visual appearance alone. In particular, changes in the concentration and distribution of eumelanin (gives color to skin) and hemoglobin are strong indicators of melanoma.

"There can be a huge lag-time before doctors even figure out what is going on with the patient," said Prof. Wong, "Our goal is to shorten that process." The AI system was trained using tens of thousands of skin images and their corresponding eumelanin and hemoglobin levels. It gives doctors objective information on lesion characteristics to help them identify or rule out melanoma before deciding if to take more invasive action. The technology could be available to doctors as early as 2018.

The research was recently presented at the 14th International Conference on Image Analysis and Recognition (ICIAR 2017, July 5-7, 2017, Montreal, Canada).

Related Links:
University of Waterloo


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of 123RF)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.